-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Genmab, Raises Price Target to $80

Benzinga·10/30/2026 13:18:05
Diffusion vocale
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $58 to $80.